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Phthalates, commonly used to make plastics more durable, are a group of endocrine 
disrupting chemicals (EDC), with potential for adverse metabolic consequences.  
Associations between exposure to 13 phthalate metabolites and the prevalence of 
metabolic syndrome (MetS) were examined among 5,409 U.S adults ≥ 18 years of 
age, who participated in the National Health and Nutrition Examination Survey from 
2005-2010. MetS was assessed using clinical and questionnaire data.  Odds Ratio 
(OR) and 95% Confidence Intervals (CI) adjusting for age, creatinine and key 
confounders, were estimated with multivariable logistic regression. Positive 
associations were observed between individual phthalate metabolites and MetS: 
(MCOP OR=1.31, 95% CI=1.40, 1.64, p-trend<.01; MCPP OR=1.39, 95% CI=1.09, 
1.77, p-trend=0.01).  In gender stratified analyses, findings with MCOPP and MCPP 
were restricted to women only. Phthalate metabolites may increase the prevalence of 
MetS; however, further studies are needed to better understand the role of EDCs in 
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Chapter 1: Background 
 
Recent changes in the number and types of chemicals in the environment have 
been associated with increasing metabolic disorders(1–4).  Increasing exposure to 
phthalates, chemicals with endocrine-disrupting properties, may in part explain these 
observed associations.  However, to date, the relationship between phthalates and 
metabolic syndrome has not been examined in epidemiological studies.  
Phthalates are a large family of chemicals primarily used to make plastics 
more flexible and durable(5). They are used to soften polyvinyl chlorides (PVCs), 
which are widely used in plastic materials, thus classifying this family of chemicals as 
a common plasticizer(5). Additionally, phthalates are used in household cleaners, 
personal care products and children’s toys. Phthalates, which include multiple parent 
compounds, are broken down into metabolites classified based on their molecular 
weight, including either low-molecular-weight (LMW) or high-molecular-weight 
phthalates (HMW)(5). Phthalates within each category have different applications, and 
toxicological properties which are described in the following sections.  
Phthalates have been associated with a number of adverse health outcomes, 
including obesity(6), diabetes(7), and heart disease(8) and cancer(9). The following 
sections describe phthalates in terms of chemical properties, applications, toxicities 
and susceptible populations. Epidemiological and mechanistic evidence linking 
phthalates to metabolic syndrome(10) will also be reviewed in addition to the public 




1.1 Phthalate Toxicities 
Phthalates are divided into two distinct categories based on their molecular 
weight, as defined by the number of carbon atoms in the chemical structure(5).  Low-
molecular-weight (LMW) phthalates (Figure 1-1) are composed of three to six 
carbons and high-molecular-weight (HMW) phthalates (Figure 1-2) are composed of 
more than six carbons(11). Phthalate properties and applications differ according to 
their molecular weight whereby water solubility decreases with increasing length of 
the carbon chain, making LMW phthalates more water soluble than HMW 
phthalates(5). Due to water solubility, LMW phthalates have a greater likelihood of 
being excreted quickly as its primary metabolite in contrast to HMW phthalates, 
which need to be oxidized further to their secondary metabolic form in order to be 
excreted(5).  As a result, HMW phthalates have a greater affinity of being stored 
longer then LMW phthalates. However, HMW phthalates, such as di-2-ethylhexyl 
phthalate (DEHP) and di-isononyl phthalate (DiNP), have greater volatility(5). 
Researchers have documented these differences, as well as potency factors, in 
multiple in-vitro studies(3).  
 
Figure 1-1. Chemical structure of Di-ethyl Phthalate (DEP), a low molecular weight 
phthalate 
 
Mankidy et al. compared HMW and LMW phthalates in terms of cytotxocity, 
endocrine disruption and lipid peroxidation in fish embryos(3). DEHP and di-ethyl 




lipid peroxidation, while dibutyl phthalate (DBP) documented the weakest overall 
potency(3). A similar study conducted in rats found DEHP and DEP once again 
exhibiting the strongest level of potency(12). However, butyl benzyl phthalate (BBzP) 
was found to be weaker in relation to DBP. The results of these studies suggest that in 
terms of endocrine disruption, DEHP and DEP exhibit the most potency while DBP 
and BBzP the weakest(13). DBP and BBzP exhibited the strongest potency when 
examining estrogenic activity(14). 
 
 
Figure 1-2. Chemical structure of Di-2-ethylhexyl phthalate (DEHP), a high molecular 
weight phthalate 
1.2 Susceptible Populations 
Humans may be exposed to phthalates through ingestion, inhalation and dermal 
contact(5). In the general population, the most common route of exposure is through ingestion 
of contaminated food and water. The dietary intake of DEHP is estimated to be the highest in 
children(10), followed by adolescents, thus making children the population most vulnerable to 
being exposed(5).  However, several studies have also found phthalate levels to be higher in 
non-Caucasian racial groups(15) and females (16)(17). Women may also be more susceptible to 
dermal exposure of phthalates due to their larger use of phthalate containing personal care 
products and make-up(16). Phthalate exposure is most prevalent among African Americans in 
comparison to other non-white minority groups(15).  Potential explanations for the racial 




1.3 Exposure Assessment 
The widespread use of phthalates results in human exposure via dietary 
ingestion of contaminated foods, dermal absorption of low molecular weight 
phthalates, inhalation of the more volatile phthalates and parenteral exposure from 
contaminated medical devices (18,19). The presence of phthalates metabolites may be 
detected in serum and blood levels, human breast milk and urine (20). These measured 
levels provide an estimate of exposure combined over all routes and sources. In a 
2008 study comparing the suitability of detecting phthalate exposure for each of the 
aforementioned measures, analytic measurements using blood, serum and breast milk 
samples were found to have limited sensitivity(20). In contrast, the study authors found 
that measuring phthalate metabolites in the urine gave more informative results.  
Overall, the availability and noninvasive nature of urine specimen collection makes it 
the most widely measured sample for phthalate exposure(21). Despite this, there are 
inconsistencies regarding phthalate exposure characterization in urine, particularly in 
how accurately the measurement reflects true exposure level.  Due to the short 
biologic half-lives of phthalates, urinary metabolite concentrations reflect exposures 
that occurred ≤1 day before the urine sample was collected(22). It is due to this reason 
that single spot urine sample measurements of phthalate metabolites are often prone 
to exposure misclassification. Nonetheless, it is agreed by multiple researchers in the 





1.4 Mechanistic Evidence  
Substantial evidence shows the potential for phthalates to disrupt hormonal 
regulation and endocrine system functionality, affecting health and reproduction in 
both humans and animals(23). This ability has earned phthalates the title of endocrine 
disrupting chemical (EDC)(24). EDCs may target any hormonal system, however, a 
number of earlier observations have found that phthalates are more likely to impart 
anti-androgenic effects and disrupt reproduction(25,26). More recently, studies in 
rodents have illustrated deregulation of cortisol, blood glucose, thyroid-stimulating 
hormone and serum insulin levels due to phthalate exposure(4). These changes have 
been shown to increase abdominal obesity and insulin resistance in human studies, 
suggesting that phthalates, as endocrine disruptors, may also play a role in metabolic 
disorders(4)(27).   
 There are three possible mechanisms by which EDCs, such as phthalates, may 
cause MetS(4). The first mechanism is the inappropriate inactivation of hormonal 
receptors such as estrogen receptors, thyroid hormone receptors and glucocorticoid 
receptors(4). Hormonal receptors are largely responsible for maintaining homeostasis 
and are only able to recognize select molecules with high affinity for receptor 
binding. These receptors are targeted by EDCs, which bind to them and subsequently 
result in reproductive and metabolic alterations (4). Bisphenol A, another chemical 
plasticizer like phthalates, has a high affinity for glucocorticoid receptors and is able 
to stimulate lipid accumulation markers and increase expression of adipocyte-specific 





The second mechanism by which EDCs act on MetS is through xenosensors, 
which regulate detoxification pathways(4). The primary purpose of xenosensors is to 
protect the body from bioaccumulation of toxic chemicals. When activated, 
xenosensors disrupt estrogen receptor pathways, as well as other neuro-receptors. 
Inadvertently, the body’s response to foreign chemicals disrupts the body’s regular 
metabolic pathways.  
The final mechanism that EDC’s act on MetS is through the activation of 
peroxisome proliferator-activated receptors (PPARs)(4). EDC’s such as phthalates 
stimulate PPARs, which regulate adipogenesis in the body(29). PPARs also have 
functions in lipid storage, insulin sensitivity control and inflammatory responses(30). It 
is because of this mechanistic evidence that exposure to phthalates is examined in 
relation to obesity(31).  
 
1. 5 Phthalate Exposure and Metabolic Syndrome 
Given these suggested biological properties, a few epidemiological studies 
have assessed phthalate exposure in relation to obesity(32), heart disease(33) and 
stroke(34). These chronic conditions are generally characterized by metabolic risk 
factors, including elevated levels of fasting glucose and cholesterol. The presence of 
multiple metabolic risk factors is referred to as metabolic syndrome (MetS)(35). 
Individuals are diagnosed with MetS when they meet three of the following five 
criteria: blood pressure >130/85 mm Hg, fasting blood glucose > 5.6mmol/1, serum 
triglyceride level >1.7mmol/1, HDL cholesterol level <1.0mmol/1 in men and <1.3 in 




No prior studies have examined the relationship between phthalate exposure 
and MetS.  However, a limited number of studies(36) have investigated the relationship 
between phthalate exposure and individual risk factors of MetS. A detailed overview 
of these studies can be found in Table A-1 in the appendix. All of the aforementioned 
studies measured phthalate exposure via individual metabolite concentrations in urine 
samples.  
1.5.1 Waist Circumference 
Seven studies have previously looked at waist circumference and body size in 
relation to phthalate exposures (6,37,32,38–41). Four of the studies utilized a cross-
sectional design(6,32,40,41), three of which were conducted in the U.S. using NHANES 
data in adults(6,40,41).  Overall detectable levels of metabolites of four phthalates: 
DEHP, DEP, DBP and BBP were primarily assessed in all of the NHANES 
studies(6,40,41) (Table A-1). All four of the studies found positive associations between 
urinary phthalates and increased waist circumference(6,32,40,41). Additionally, 
Teitelbaum et al., conducted a longitudinal analysis to assess phthalate exposure in 
relation to waist circumference among children(39). The authors reported a positive 
association with phthalate exposure and increased waist circumference; however, the 
results were inconsistent among the phthalate metabolites measured(39). The strongest 
association was observed among girls exposed to monoethyl phthalate (MEP), in 
comparison to the other metabolites examined. However, the authors hypothesize that 
these results may be the result of the wide concentration range of metabolites in the 
study population(39). Of the nine individual metabolites measured, MEP was the only 




10% of the study population(39). Across all six studies(6,31,37–40), the strongest 
associations between waist circumference and phthalate exposure was found among 
DEP and DEHP metabolites. In one other longitudinal analysis which examined 
phthalate exposure in relation to waist circumference among 152 overweight/obese 
adults undergoing weight loss, the relationship was found to be null(37).   
1.5.2 Insulin Resistance 
Insulin resistance is another component of metabolic syndrome that has been 
widely studied in relation to phthalate exposure (7,40,42–44). Five cross-sectional studies 
have found a positive correlation between exposure to phthalates and insulin 
resistance, as measured by the homeostatic model assessment index (HOMA), which 
is an index used to quantify insulin resistance and beta-cell function (40,45,42,46); four 
studies used NHANES data(40,42,46) while one used an urban Chinese cohort(45). Two 
studies focused on women and another sampled the elderly(43)(47), limiting the 
generalizability to all adults. Huang et al., used a cross-sectional analysis to 
characterize diabetes prevalence across different racial groups exposed to 
phthalates(42) with results suggesting that associations between phthalates and insulin 
resistance may vary by race and gender, especially among Hispanics and Blacks. 
Three other cross-sectional studies examined phthalate exposure in relation to Type 2 
diabetes among adults(47,7,44).  Type 2 diabetes was defined on the basis of a self-
reported physician’s diagnosis and fasting blood glucose(47) in one study and only 
self-reported physician’s diagnoses in the others(7,44)(48). All three studies found 
borderline and/or statistically significant associations with urinary phthalate 




1.5.3 Other Metabolic Syndrome Components 
Additional MetS risk factors, including triglyceride level, HDL cholesterol 
and high blood pressure, are understudied in relation to phthalate exposure. Only two 
NHANES analyses by Shiue et al., and Trasande et al., examined these relationships, 
with positive associations reported between blood pressure and urinary phthalate 
metabolites(8,49). Although prior studies have included these MetS components as 
adjustment factors in their analyses, they have not been included as outcome variables 
in studies of phthalate exposure(50). Results from the two prior NHANES analyses(8,49) 
support a relationship between phthalate exposure and high blood pressure, however 
analyses were not conducted in relation to other MetS components.   
 There are limitations to the studies conducted above that should be 
considered. Firstly, there are inconsistencies among the outcome measures as several 
studies utilized a self-reported outcome while others used examination data. 
Secondly, issues related to co-exposures to confounding compounds, selection of 
control populations in the cohort studies and variability in data analysis complicate 
data interpretation. However, overall there is some evidence supporting the 
relationships between phthalate exposure and insulin resistance and waist 
circumference. Less evidence exists for the other three components of MetS and no 
prior study has examined metabolic syndrome as the overall outcome. Limited 
evidence also exists regarding differences by gender, among ethnically diverse 
populations and by type of phthalate. This study addressed these scientific gaps in the 




1.6 Public Health Significance  
Heart disease, stroke and type 2 diabetes have a large global impact on the 
lives of millions of people. Combined, these diseases affect 50% of the global 
population and accounted for 30% of the total mortality in 2012(51). Diabetes and 
stroke are also included in the top ten leading causes of death in the U.S. Obesity 
rates continue to rise and it is projected that if the current trend continues, 86.3% of 
adults will be overweight or obese by 2030(52).  All of these diseases are considered to 
be metabolic disorders and individuals at risk of MetS are at greater risk of acquiring 
any of these diseases. Prevention initiatives and changes in national public health 
policies have reduced the risk of MetS within the last 10 years(53). However, a fifth of 
the United States population still remain at high risk for MetS(54).  
Sedentary behaviors, genetic factors and exposure to environmental chemicals 
such as phthalates promote the increasing risks of obesity, diabetes and 
cardiovascular diseases(55). Widespread industrial use of phthalates in children’s toys, 
make-up, perfumes, plastic food and storage containers as well as household cleaning 
supplies lead to a greater prevalence of human exposure(34). Because the effects of 
phthalate exposure are only recently being studied, it is difficult to determine what the 
long-term effects of such a widespread exposure will be.  
This study aims to evaluate the relationship between phthalate exposure and 
MetS among U.S adults and to examine differences in associations by gender. This 
will be evaluated through a cross sectional analysis of the 2005-2010 survey data 
from the U.S National Health and Nutrition Examination Survey (NHANES). This 




phthalate exposures and the independent risk factors that define MetS. Findings from 
this analysis will further our understanding of endocrine disruptors and their potential 






Chapter 2: Methods 
 
2.1 Study Population 
The study objectives were evaluated through a cross-sectional analysis of 
adults who participated in the NHANES 2005-2010 survey years. NHANES is a 
nationally representative sample of non-institutionalized U.S. citizens(56). About 5000 
people are surveyed each year and the data is released by the National Center for 
Health Statistics (NCHS) in two year cycles. The NHANES survey is a stratified, 
multistage probability sample. U.S. counties are partitioned into strata based on 
regional, economic and racial characteristics. Two primary sampling units are then 
selected from each strata. Within each sampling unit, neighborhoods are selected, 
from which random samples of households are selected. Neighborhoods that have a 
large proportion of oversampled age, ethnic and income groups have a greater 
likelihood of being chosen than others. Finally within the selected households, 
individuals within designated demographic sub-domains (i.e. gender, race, ethnicity 
and age) are randomly selected to be participants(56).  
Because NHANES is a nationally representative sample, all demographic 
domains are examined. Hispanics, African Americans, Asians and individuals over 
the age of 60 are oversampled to ensure a suitable representation within the survey 
population.  
2.1.1 Analytic Sample 
The sample included participants of NHANES 2005-2010 (N=31034). Figure 




data from the NHANES survey conducted in 2011-2012 is available, this survey year 
was not included as phthalate measurements were derived from a different subsample 
then previous years. Only participants whose urine was measured for the presence of 
phthalate metabolites were retained in the sample (n=7901). Subjects were excluded 
if they were under the age of 18 (n=2307) since metabolic syndrome criteria for 
children is defined differently from adults(1).  Individuals undergoing dialysis (n=8) 
were excluded because these treatments may affect the biological mechanism of 
interest. Finally females identified as pregnant or possibly pregnant (determined by 
urine test at exam; n=177) were also excluded as pregnancy alters biomarker levels. 
After exclusions, the final analytic sample consisted of 5409 participants.  
 
2.1.2 Data Collection 
The following describes NHANES data collection procedures for the 
independent and dependent variables. In addition to the main variables of interest, 
NHANES collected data on relevant demographic, health and lifestyle factors via 
questionnaires administered during the home interview. 
Urine samples were collected from all eligible participants ages 6 and above. 
Participants were asked to report their last urine void before coming to the mobile 
examination center. Urine samples were stored in frozen conditions until they were 
sent to NCHS to be tested. Phthalate metabolites were measured using high 
performance liquid chromatography-electrospray ionization-tandem mass 
spectrometry (HPLC-ESI-MS/MS).  As phthalates have a short half-life, meaning the 




conjugation efficiency was monitored to rapidly detect metabolites at the lowest limit 
of detection.   
NHANES uses a combination of examination and laboratory data to examine 
the multiple components of metabolic syndrome. As part of the data collection 
procedures, participants provided a blood sample at the mobile examination center, 
after which the samples were frozen and stored in -20°C temperature until shipped to 
headquarters for testing.  Serum triglyceride levels and HDL cholesterol levels were 
only assessed from blood draws conducted during morning examinations.  
Participants were asked to fast for 8.5 hours or more (but less than 24 hours) before 
giving a blood sample. Only participants over the age of 12 were asked to give fasting 
samples and measurements were conducted only among a subsample of participants 
that had received all other laboratory examinations. Fasting glucose levels were 
measured similarly to serum triglyceride and HDL cholesterol levels. Participants 
were given an initial blood test and were then asked to consume a glucose tolerance 
test beverage before providing another blood sample 2 hours later. An oral glucose 
tolerance test was also administered.  
Waist circumference and blood pressure were measured by NHANES 
personnel at examination centers. Waist circumference was measured for all 
participants. Examiners first marked the measurement site and then used a calibrated 
measuring tape to assess the circumference of the waist. Measures were recorded in 
centimeters. Blood pressure was measured in all examinees.  
Participants were asked to sit quietly for 5 minutes before three consecutive 




previous measures were disrupted due to movement, noise or incorrect readings. 
Blood pressure was measured using a mercury sphygmomanometer during the 2005-
2008 survey cycle years. In the 2009-2010 survey, a new automated measurement 
protocol was introduced to supplement the sphygmomanometer measure.  
2.2 Variable Definitions 
2.2.1 Independent Variable 
Individual phthalate metabolites were the main exposures assessed in this 
analysis. Only metabolites consistently detected in the urine across all three survey 
years were analyzed. 13 phthalate metabolites belonging to the following 9 parent 
compounds were included in this study: diisodecyl phthalate (DiDP), di(2-ethylhexyl) 
phthalate (DEHP), di-n-butyl phthalate (DBP), diethyl phthalate (DEP), diisononyl 
phthalate (DiNP), diisobutyl phthalate (DiBP), dimethyl phthalate (DMP), dioctyl 
phthalate (DOP) and butyl benzyl phthalate (BBP). For individuals assessed as having 
phthalate concentrations below the LOD, the LOD divided by the square root of two 
was reported by NHANES. A categorical indicator variable was created by NHANES 
for each metabolite to determine whether phthalate concentrations were above or 
below the LOD. Due to changes in LOD values across survey years, the highest LOD 
value for the years was used. A new indicator variable was created to determine 
whether concentrations remain above the new LOD value. Table 2-1 summarizes the 
LOD value and concentration amounts for each metabolite.  
Urinary concentrations of phthalates were reported by NHANES on a 
continuous scale. However, each metabolites was analyzed as a categorical variable 




Distributions of each metabolite were reviewed through estimation of means, 
geometric means, and median values. Because metabolites were not normally 
distributed, metabolites were log transformed before geometric means could be 
calculated. For comparative analysis spearman correlation coefficients were 
calculated to assess metabolite relationships. 


























Mono-2-ethylhexyl MEHP 1.2 









Mono-n-butyl phthalate MnBP Dibutyl phthalates LMWb 0.6 
Mono-ethyl phthalate MEP Diethyl phthalate LMW 0.5 





a HMW: High Molecular Weight 
b LMW: Low Molecular Weight 
c  LOD: Limit of Detection 
1 Highest LOD for each metabolite across the three survey years was used for the lower 
limit of detection. 
 
This analysis accounted for urine concentration and flow rate by adjusting for 
creatinine in the regression models. Previous studies have documented that 
creatinine-adjusted urinary metabolite concentrations better correlate with blood or 




two methods by which creatinine adjusted chemical values may be determined in a 
population. The first is that individual creatinine-adjusted urinary chemicals are 
analyzed as the independent variable used to determine whether the chemical of 
interest is associated with the outcome (58). The second method involves adjusting for 
creatinine corrected chemical values as the dependent variable (58). However, in both 
models the creatinine corrected chemical may be significantly associated with the 
outcome because the individual outcome or other model covariates were related to 
urinary creatinine. To overcome this limitation it is recommended to adjust for 
creatinine concentrations separately from the chemical as an independent variable, 
allowing creatinine to be adjusted for the urinary chemical of interest as well as other 
covariates included in the model(58).  
2.2.2 Dependent Variable 
The dependent variable was Metabolic Syndrome (MetS), defined by the 
presence of at least 3 of the following metabolic risk factors: blood pressure >130/85 
mm Hg, fasting blood glucose > 5.6mmol/1, serum triglyceride level >1.7mmol/1, 
HDL cholesterol level <1.0mmol/1 in men and <1.3 in women and waist 
circumference >102cm in men and >88cm in women(59).  All 5 criteria were reported 
in NHANES as continuous variables. MetS was analyzed as a dichotomous variable 
(yes/no).  
Cutoffs for the above mentioned MetS components were based off of the U.S 
National Cholesterol Education Program Adult Treatment Panel III (ATPIII)(59). Each 
component was based on a single measurement taken at the examination portion 




reported, the mean systolic and diastolic blood pressure measurements for each 
participant were used to define the variable. Individuals taking medication to lower 
their blood pressure were also considered to be hypertensive based on a cross-
tabulation of the two variables.  
2.2.3 Covariates 
Gender, race, diet, socioeconomic status, total calorie intake, smoking 
behaviors and creatinine were assessed as possible covariates. Age was reported as 
the participant’s age in years at the time of the interview. Imputed dates of birth were 
calculated by NHANES if missing. Adults over the age of 85 were all recorded as 85 
to maintain anonymity. Race was recorded based on reported race and ethnicity and 
includes the following categories: non-Hispanic white, non-Hispanic black, Mexican 
American and other. The NHANES data also included “other Hispanic” and “other” 
categories. Other Hispanics were coded as other due to sample proportions lower than 
the actual U.S. population for that group as well as based on NHANES 
recommendations(60). Asian Americans could not be differentiated as a racial group as 
they were not recognized as a separate racial category by NHANES until the 2011-
2012 survey cycle. Gender was self-reported as either male or female. 
Socioeconomic status was assessed by both education and income variables. 
Education was defined as some high school, high school diploma, some college or 
Associates degree and college degree or higher. Adult education information was 
only obtained by NHANES for participants greater than or equal to the age of 20. The 
income to poverty ratio was used to define individual’s income. An individual was 




of 1.0 is considered as the federal poverty threshold and values above 1.00 indicate 
income above poverty. Values above 5.0 were coded as 5.0 to protect participant’s 
anonymity. In the present analysis income was categorized based on whether 
individuals were above or below the federal poverty threshold. Individuals who chose 
not to respond or did not know the correct answer were coded as missing.  
Dietary questionnaires were used to assess participant’s diet. Calorie intake 
was determined by total energy (kcal) and was assessed as a continuous variable. 
Finally, smoking behavior was determined by a combination of two variables asking 
whether participants had smoked at least 100 cigarettes in their life and whether they 
currently smoke cigarettes. Smoking status was categorized as never, former or 
current; non responses were coded as missing.    
2.3 Statistical Analysis 
All analyses conducted accounted for the NHANES complex survey sampling 
design. Univariable analyses including frequency distributions and calculations of 
mean (standard deviations) and median (interquartile range) values were estimated to 
evaluate the distribution of all covariates, phthalate concentrations and MetS 
variables by gender. Gender differences were assessed using t-tests and chi-square 
tests. Correlations between phthalate metabolites were estimated by Spearman 
correlation coefficients. Phthalate metabolites were divided into quartiles based on 
the overall distribution of each metabolite in the sample population. In addition to the 
13 individual phthalates, metabolites were combined into molar sums that represent 
similar biologic activity and use (LMW, HMW and DEHP). The concentrations of 




and MiBP. HMW phthalate concentrations were expressed as the sum of MCNP, 
MCOP, MiNP, MCPP, MEHP and MBzP. Finally, DEHP metabolite concentrations 
were calculated by adding the molarities of MEHP, MECPP, MEHHP and MEOHP. 
Bonferroni corrections were not applied as this was an exploratory analysis.   
Odds ratios and 95% confidence intervals were estimated using multivariable 
logistic regression. Age-adjusted logistic regression and age and gender adjusted 
logistic regression models were conducted initially to assess associations between 
individual phthalate metabolites and MetS. Subsequently, multivariable regression 
was performed, adjusting for age, gender, race, education, poverty to income ratio 
and total calorie intake. Potential confounders were selected a priori based on 
previous literature. All of the aforementioned models adjusted for urinary creatinine.   
Interaction by gender was tested by modeling an interaction term for each 
individual phthalate metabolite and gender. Likelihood ratio tests were used to 
compare multivariable models with and without the interaction term. Variance 
Inflation Factor (VIF) and tolerance tests were conducted to check for 
multicollinearity. Finally, model diagnostics tests were used to determine the overall 
fit of the model.  
Previous studies have found prevalence of MetS to be higher among 
women(54). To evaluate potential gender differences, final multivariable models were 
stratified by gender. Tests for trend were performed by modeling phthalate exposures 







2.4 Human Subjects Determination 
The National Health and Nutrition Examination Survey was approved by the 
National Center for Health Statistics research ethics review board. The survey has 
received approval from the review board for every survey cycle since 1999. 
NHANES obtains informed human consent before any examinations are conducted. 
This analysis used de-identified human data from NHANES and obtained exemption 
from further review from the Institutional Review Board of the University of 




Chapter 3: Results 
Table 3-1 describes the distribution of the study population based on key 
sociodemographic characteristics by gender. The mean age of the sample was 
approximately 47.84 years (std.dev: 19.1). There were slightly more men (n=2802) 
than women (2717) in the sample. The distribution of race/ethnicity was similar 
between men and women, with approximately 70% White, 12% Black, 10% Hispanic 
and 10% multiracial or other. Education was fairly evenly distributed across having a 
high school degree, some college education or having a college degree.  However, 
fewer participants reported having less than a high school degree. The majority of the 
study population was above the federal poverty threshold (men=82% & 
women=78%). The mean calorie intake for the population was 2449 (std.dev=21.3) 
for men and 1769 (std.dev=16.4) for women and approximately 50% of men and 
women were never smokers. Calorie intake, poverty income ratio, smoking status and 
urinary creatinine concentrations were significantly different by gender (p <0.01).  
 





N (%)a N (%)a 
Gender 2802 (49.04) 2717 (51.1)  
Age   0.43 
18-27 542 (19.2) 505 (16.0)  
28-37 430 (17.9) 411 (16.5)  
38-47 444 (20.3) 465 (20.7)  
48-57 454 (19.6) 390 (18.2)  
≥58 932 (23.1) 946 (28.6)  
Race/ Ethnicity (%)   0.23 
White 1363 (70.0) 1281 (70.3)  
Black   588 (10.7)   584 (12.2)  







N (%)a N (%)a 
Other   333 (10.0)   365 (10.4)  
Education (%)   0.06 
< High School 743 (19.1) 710 (18.0)  
High School Degree 648 (24.4) 633 (25.7)  
Some College or AA degree 669 (29.3) 720 (30.7)  
≥College Degree 536 (27.2) 489 (25.6)  
Poverty to Income Ratio (PIR)   < 0.01 
Below poverty (PIR < 1.0)   707 (17.5)   826 (21.4)  
At or above poverty (PIR ≥1.0) 2095 (82.5) 1891 (78.6)  
Smoking Status   0.01 
Never smoker 788 (53.0) 494 (51.0)  
Former smoker     120 (7.9) 74 (6.6)  
Current smoker 549 (39.0) 438 (42.4)  
 Mean (SD) b 
Body Mass Index 28.6 ± 0.13 29.03 ± 0.17    0.03 
Total Calorie Intake 2449.9 ± 21.3 1769 ± 16.4 < 0.01 
Urinary creatinine (mg/dL) 146.5 ± 2.0 112.4 ± 1.8 < 0.01 
Metabolic Syndrome Components                                      
Metabolic Syndrome (n,%) a 521 (16.8) 628 (19.8) < 0.01 
Waist Circumference (cm) 100.6 ± 0.4 95.7 ± 0.3 < 0.01 
Systolic blood pressure (mm of Hg) 125.3 ± 0.37 121.6 ± 0.5 < 0.01 
Diastolic blood pressure (mm of Hg) 71.1 ± 0.37 68.2 ± 0.33 < 0.01 
Serum triglycerides (mmol/1) 1.6 ± 0.03 1.4 ± 0.03 < 0.01 
Serum HDL (mmol/1) 1.2 ± 0.01 1.5 ± 0.01 < 0.01 
Serum glucose (mmol/1) 6.1 ± 0.05 5.9 ± 0.06 < 0.01 
a Numbers are reported as total n and weighted sample percent 
b Values are reported as weighted sample mean and standard deviation 
c Gender differences calculated using t tests for continuous variables and chi square 
tests for categorical variables.  
 
 
Statistically significant gender differences were found for MetS as well as its 
individual components (p <0.01).  Although mean levels of the individual MetS 
components were higher among men, the prevalence of MetS was greater among 
women (19.8%) than men (16.8%). Mean values for each MetS components were 







Table 3-2. Distribution of phthalate metabolite in NHANES (2005-2010) 
 
Metabolite Mean (SD) 
Median (IQRa) 
Geometric 
Mean (95% CI) 
% below 
LOD 
      
MEP 403.4 ± 22.6 83.2  (31.5, 251.1)     4.5 (4.5, 4.6) 0.1 
MECPP 73.8 ± 5.5 25.9 (12.4, 57.1) 3.3 (3.2, 3.4) 0.1 
MEHHP 55.7± 4.1 17.1 (7.8, 39.8) 2.9 (2.8, 3.0) 0.4 
MnBP 41.9 ± 5.5 17.3 (8.4, 32.2) 2.8 (2.7, 2.6) 0.5 
MEOHP 32.1 ± 2.4 10.5 (4.7, 23.0) 2.4 (2.3, 2.5) 0.9 
MCOP 21.5 ± 1.5 6.5 (3.0, 16.9) 2.0 (1.9, 2.1) 2.4 
MBzP 17.9 ± 3.1 6.8 (2.9, 15.4) 1.9 (1.8, 1.9) 1.4 
MiBP 15.4 ± 2.7 6.9 (3.1, 13.3) 1.8 (1.7, 1.9) 1.2 
MCNP 5.7 ± 0.4 2.5 (1.3, 4.9) 0.9 (0.9, 1.0) 6.2 
MCPP 5.5 ± 0.4 2.4 (1.1, 4.9) 0.9 (0.8, 0.9) 2.7 
MEHP 8.0 ± 0.7 1.9 (0.9, 4.9) 0.8 (0.8, 0.9) 28.6 
MMP 6.2 ± 2.0 0.8 (0.8, 2.3) 0.2 (0.2, 0.3) 52.1 
MiNP 2.3 ± 0.2 0.87 (0.9, 0.9) 0.1 (0.01, 0.1) 78.5 
a IQR: Interquartile Range 
 
Distributions of individual phthalate metabolites were evaluated in the study 
population (Table 3-2). Of the 13 metabolites, two metabolites MMP and MiNP had 
concentrations below the LOD, 52.1% and 78.5% respectively, for more than half of 
the sample population. Concentrations for MEP (geometric mean = 4.5, 95% CI: 4.5, 
4.6), MECPP (geometric mean = 3.3, 95% CI: 3.2, 3.4), MEHHP (geometric mean = 
2.9, 95% CI: 2.8, 3.0) and MnBP (geometric mean = 2.8, 95% CI: 2.7, 2.9) were the 
highest among all participants. MinP (geometric mean = 0.05, 95% CI: 0.01, 0.08), 
MMP (geometric mean = 0.25, 95% CI: 0.18, 0.32) and MEHP (geometric mean= 
0.8, 95% CI: 0.8, 0.9) had the lowest concentrations. Strong statistically significant 
correlations were found between MEHHP and MECPP (r=0.94), MEOHP and 




(r=0.74) were also strongly correlated with MnBP. Correlations between other 
metabolites were not as strong; however, all correlations were found to be statistically 
significant (p<.001 for all) (Table 3-3). Observed correlations were generally stronger 
for women than men. (Table A-2 & A-3).  
Table 3-3. Spearman correlation coefficients between phthalate metabolites NHANES 
2005-2010 
 
 mcnp mcop mecpp mnbp mcpp mep mehhp mehp mmp minp meohp mbzp mibp 
MCNP 1 0.61 0.50 0.36 0.72 0.18 0.45 0.34 0.11 0.35 0.46 0.35 0.43 
MCOP  1 0.46 0.39 0.59 0.24 0.41 0.33 0.20 0.28 0.43 0.36 0.40 
MECPP  1 0.54 0.56 0.30 0.94 0.74 0.22 0.34 0.94 0.47 0.48 
MnBP  1 0.56 0.42 0.57 0.46 0.30 0.23 0.58 0.69 0.74 
MCPP  1 0.25 0.55 0.42 0.19 0.38 0.57 0.50 0.54 
MEP  1 0.31 0.26 0.26 0.15 0.32 0.32 0.37 
MEHHP  1 0.79 0.23 0.36 0.98 0.51 0.51 
MEHP  1 0.20 0.42 0.79 0.41 0.42 
MMP  1 0.16 0.23 0.24 0.27 
MiNP  1 0.35 0.18 0.18 
MEOHP  1 0.52 0.52 
MBzP  1 0.60 
MiBP  1 
Correlations were statistically significant at the p < 0.001 level. 
 
Associations with MetS across quartiles of 13 phthalate metabolites are 
presented in Table 3-4.  Age was significantly associated with MetS (p< 0.01) and 
was adjusted for in the first model along with creatinine. A statistically significant 
linear trend was observed for MCOP (p trend: 0.02), MECPP (p trend: 0.03) and 
MCPP (p trend: 0.03) in the age-adjusted models.  No other statistically significant 
associations were observed between individual phthalate metabolites and MetS in age 
and creatinine adjusted models. 
In models additionally adjusted for gender, similar linear trends were 
observed with MCOP, MECPP and MCPP. However, individual estimates were 
























P trend OR  
(95% CI) 
P trend 
MEP        
Q1 295/1058 REF  REF  REF  
Q2 283/1070 1.02 (0.79, 1.32) 1.05 (0.81, 1.37) 0.86 (0.64, 1.17) 
Q3 273/1078 0.91 (0.69, 1.18) 0.92 (0.70, 1.21) 0.90 (0.68, 1.21) 
Q4 275/1077 1.04 (0.32, 0.82)a 1.04 (0.82. 1.32) 0.89 (0.66, 1.19) 
   0.88  0.94  0.43 
MCOP        
Q1 285/1098 REF  REF  REF  
Q2 277/1050 0.74 (0.58, 0.95)a 0.75 (0.59, 0.96)a 1.31 (1.40, 1.64)a 
Q3 291/1056 0.93 (0.74, 1.17) 0.93 (0.74, 1.18) 1.43 (1.06, 1.92)a 
Q4 273/1079 1.04 (0.81, 1.33) 1.04 (0.81, 1.34) 1.30 (1.16, 1.89)a 
   0.02  0.02  0.004 
MECPP        
Q1 263/1091 REF  REF  REF  
Q2 281/1071 0.76 (0.57, 1.02) 0.78 (0.59, 1.03) 1.16 (0.91, 1.48) 
Q3 310/1042 0.84 (0.64, 1.11) 0.86 (0.65, 1.12) 1.43 (1.10, 2.13)a 
Q4 272/1079 1.11 (0.87, 1.42) 1.12 (0.88, 1.43) 1.48 (0.96, 1.77) 
   0.03  0.04  0.05 
MnBP        
Q1 286/1070 REF  REF  REF  
Q2 307/1043 0.97 (0.68, 1.40) 1.06 (0.73, 1.53) 1.19 (0.86, 1.63) 
Q3 272/1083 1.15 (0.85, 1.55) 1.24 (0.92, 1.68) 1.02 (0.75, 1.38) 
Q4 261/1087 1.03 (0.78, 1.35) 1.07 (0.82. 1.40) 0.87 (0.58, 1.29) 
   0.94  0.59  0.35 
MBzP        
Q1 312/1047 REF  REF  REF  
Q2 289/1067 1.09 (0.85, 1.40) 0.86 (0.61, 1.23) 1.02 (0.80, 1.30) 
Q3 265/1078 1.06 (0.79, 1.45) 0.94 (0.70, 1.27) 0.99 (0.72, 1.36) 
Q4 260/1091 1.20 (0.85, 1.70) 0.91 (0.67, 1.23) 1.05 (0.72, 1.53) 
   0.36  0.48  0.85 
MMP        
Q1 667/2423 REF  REF  REF  
Q2 187/780 1.21 (0.95, 1.55) 1.23 (0.96, 1.57) 0.88 (0.69, 1.13) 
Q3 272/1080 1.10 (0.79, 1.52) 1.12 (0.81, 1.54) 0.83 (0.65, 1.07) 
   0.10  0.09  0.11 
MEHP        
Q1 438/1379 REF  REF  REF  
Q2 205/696 1.17 (0.88, 1.57) 1.18 (0.89, 1.57) 0.99 (0.75, 1.31) 
Q3 276/1963 1.17 (0.88, 1.56) 1.18 (0.88, 1.58) 1.03 (0.77, 1.38) 




















P trend OR  
(95% CI) 
P trend 
   0.42  0.41  0.35 
MCNP        
Q1 283/1070 REF  REF  REF  
Q2 313/1059 0.98 (0.78, 1.22) 0.97 (0.78, 1.22) 1.19 (0.95, 1.49) 
Q3 277/1058 1.17 (0.89, 1.53) 1.17 (0.90, 1.53) 1.17 (0.94, 1.47) 
Q4 253/1096 1.09 (0.8, 1.39) 1.09 (0.86, 1.40) 1.07 (0.87, 1.33) 
   0.88  0.90    0.71 
MCPP        
Q1 287/1066 REF  REF  REF  
Q2 271/1087 0.78 (0.60, 1.01) 0.79 (0.61, 1.02) 1.03 (0.76, 1.38) 
Q3 278/1079 0.74 (0.54, 1.00) 0.75 (0.55, 1.01) 1.12 (0.84, 1.50) 
Q4 290/1051 0.85 (0.65, 1.11) 0.85 (0.66, 1.11) 1.39 (1.09, 1.77)a 
   0.03  0.04  0.01 
MEHHP        
Q1 280/1076 REF  REF  REF  
Q2 276/1077 0.79 (0.59, 1.05) 0.80 (0.60, 1.06) 1.14 (0.88, 1.48) 
Q3 299/1049 0.85 (0.30, 1.13) 0.86 (0.64, 1.15) 1.27 (0.93, 1.74) 
Q4 271/1081 1.01 (0.79, 1.29) 1.01 (0.79, 1.29) 1.25 (0.92, 1.70) 
   0.08  0.09  0.61 
MiNP        
Q1 942/3381 REF  REF  REF  
Q2 184/902 1.00 (0.80, 1.26) 0.99 (0.79, 1.25) 1.05 (0.83, 1.34) 
   0.98  0.95  0.68 
MEOHP        
Q1 288/1066 REF  REF  REF  
Q2 270/1081 0.91 (0.68, 1.22) 0.92 (0.69, 1.24) 0.97 (0.74, 1.28) 
Q3 307/1046 0.84 (0.64, 1.09) 0.86 (0.66, 1.12) 1.27 (0.92, 1.77) 
Q4 261/1090 1.15 (0.89, 1.49) 1.16 (0.90, 1.49) 1.08 (0.81, 1.46) 
   0.22  0.28  0.35 
MiBP        
Q1 288/1069 REF  REF  REF  
Q2 284/1076 0.83 (0.63. 1.10) 0.88 (0.67, 1.16) 1.08 (0.81, 1.42) 
Q3 275/1065 0.92 (0.72, 1.17) 0.96 (0.75, 1.24) 1.00 (0.73, 1.37) 
Q4 279/1073 0.87 (0.68, 1.10) 0.89 (0.69, 1.15) 1.03 (0.77, 1.37) 
   0.29  0.50  0.99 
a  Statistically Significant (p<0.05)  
1 All analyses adjusted for age and creatinine 
2 All analyses adjusted for age, gender and creatinine 






Results from the multivariable analyses are also summarized in Table 3-4. 
This model included adjustments for age, gender, race, education, income, calorie 
intake and creatinine. Increasing levels of MCOP, MECPP and MCPP were 
significantly associated with an increase in the prevalence of MetS (p trend: 0.004, 
0.05, and 0.1, respectively). More specifically, when comparing those in the highest 
to lowest quartiles, the odds of MetS was elevated: MCOP (1.3, 95% CI: 1.06, 1.92), 
MECPP (1.4, 95% CI: 1.10, 2.13) and MCPP (1.4, 95% CI: 1.09, 1.77). .  
Table 3-5 presents results from the gender stratified multivariable models 
examining the associations of phthalate metabolites with MetS. Overall, the odds of 
MetS was higher among women exposed to phthalate metabolites than men. No 
statistically significant associations were observed for men. However, select 
metabolites demonstrated an increase in the odds of MetS for women.   Similar to the 
findings from the overall multivariable analyses, MCOP (1.7, 95% CI: 1.3, 2.2) and 
MCPP (1.7, 95% CI: 1.3, 2.4) demonstrated an increased odds of MetS when 
comparing women in quartile 4 to those in quartile 1. In contrast, a significant inverse 
association was observed among women in the highest quartile of MnBP (0.57, 95% 
CI: 0.37, 0.87) and MEHP (0.57, 95% CI: 0.34, 0.96) compared to those in the 
lowest. A statistically significant p-trend was observed for MCOP, MCPP, MnBP and 
MEHP, suggesting that among women, there may be evidence of a potential dose 
response relationship with MetS for these metabolites. However, tests for interaction 






Table 3-5.  Associations of phthalate metabolites with MetS by gender in NHANES 
(2005-2010) 
 








adjusted model2  









1.26 (0.94, 1.70) 
1.02 (0.74, 1.40) 




1.05 (0.76, 1.44) 
1.14 (0.80, 1.62) 




1.28 (0.93, 1.78) 
1.07 (0.78, 1.47) 




1.25 (0.85, 1.84) 
1.09 (0.78, 1.53) 










1.17 (0.92, 1.50) 
1.44 (0.97, 2.14) 




1.41 (0.98, 2.04) 
1.35 (0.92, 1.99) 




1.15 (0.86, 1.52) 
1.33 (0.93, 1.89) 




1.20 (0.89, 1.60) 
1.46 (0.99, 2.16) 










0.94 (0.69, 1.30) 
1.28 (0.85, 1.41) 




1.09 (0.77, 1.56) 
1.38 (0.97, 1.97) 




0.97 (0.67, 1.41) 
1.23 (0.82, 1.85) 




0.99 (0.68, 1.46) 
1.24 (0.79, 1.94) 










1.05 (0.78, 1.43) 
1.15 (0.86, 1.55) 




1.22 (0.74, 1.99) 
0.90 (0.60, 1.34) 




0.97 (0.73, 1.28) 
1.17 (0.82, 1.66) 




0.94 (0.70, 1.26) 
1.15 (0.81, 1.63) 










1.02 (0.74, 1.41) 
1.23 (0.83, 1.83) 




0.93 (0.63, 1.39) 
1.04 (0.71, 1.52) 




0.91 (0.62, 1.32) 
1.27 (0.84, 1.93) 




1.08 (0.75, 1.56) 
1.42 (0.97, 2.07) 










1.17 (0.80, 1.70) 
1.06 (0.74, 1.51) 




0.65 (0.40, 1.05) 
0.88 (0.57, 1.37) 




1.14 (0.78, 1.63) 
1.07 (0.74, 1.55) 




1.08 (0.76, 1.53) 
0.91 (0.63, 1.33) 










0.96 (0.72, 1.28) 
1.41 (0.98, 2.02) 




1.24 (0.84, 1.82) 
1.26 (0.85, 1.88) 




0.86 (0.63, 1.19) 
1.35 (0.93, 1.97) 




0.91 (0.67, 1.24) 
1.41 (0.98, 2.03) 
0.97 (0.66, 1.43) 
0.62 












adjusted model2  







0.96 (0.65, 1.41) 
0.78 (0.55, 1.12) 
0.61 (0.39, 0.96)a 
0.02 
REF 
1.13 (0.76, 1.70) 
1.41 (0.96, 2.07) 
1.16 (0.75, 1.80) 
0.32 
REF 
0.94 (0.62, 1.42) 
0.77 (0.51, 1.15) 
0.60 (0.37, 0.99)a 
0.03 
REF 
0.93 (0.60, 1.44) 
0.77 (0.50, 1.16) 









0.76 (0.50, 1.14) 




1.03 (0.76, 1.41) 




0.76 (0.50, 1.14) 




0.76 (0.48, 1.18) 






























0.88 (0.67, 1.16) 
1.21 (0.85, 1.73) 




1.06 (0.72, 1.32) 
0.91 (0.60, 1.38) 




0.80 (0.58, 1.09) 
1.11 (0.75, 1.64) 




0.81 (0.60, 1.10) 
1.10 (0.74, 1.63) 










1.05 (0.75, 1.51) 
1.29 (0.90. 1.85) 




1.08 (0.76, 1.52) 
0.75 (0.49, 1.13) 




1.04 (0.71, 1.51) 
1.42 (0.95, 2.14) 




0.96 (0.67, 1.36) 
1.33 (0.88, 2.02) 










1.23 (0.85, 1.77) 
1.16 (0.83, 1.62) 




0.97 (0.71, 1.32) 
0.91 (0.60, 1.38) 




1.24 (0.87, 1.78) 
1.21 (0.83, 1.75) 




1.20 (0.83, 1.74) 
1.10 (0.76, 1.60) 
1.31 (0.70, 1.83) 
0.65 
a  Statistically Significant (p<0.05)  
1 All analyses adjusted for age and creatinine 








Table 3-6 presents the associations of LMW, HMW and DEHP metabolites in 
relationship to MetS by gender. Among women, the molar sum of HMW metabolites 
was significantly associated with an increased prevalence of MetS in multivariable 
models (ORQ4vsQ1=1.55, 95% CI: 1.1, 2.2, p-trend=0.01).  In contrast, results from 
multivariable adjusted analyses suggest that the odds of MetS was greater in men for 
DEHP metabolites (ORQ4vsQ11.5, 95% CI: 0.9, 2.4); however, these results were not 
statistically significant. No statistically significant results were observed for the molar 
sum of LMW metabolites.  
 
Table 3-6. Associations of molar summed phthalate metabolites by gender in NHANES 
(2005-2010) 
 








adjusted model2  









1.03 (0.70, 1.51) 
0.75 (0.53, 1.05) 




0.78 (0.54, 1.13) 
0.84 (0.51, 1.36) 




1.02 (0.71, 1.48) 
1.12 (0.74, 1.69) 




1.00 (0.73, 1.38) 
0.76 (0.54, 1.07) 










1.09 (0.70, 1.69) 
1.03 (0.67, 1.59) 




0.98 (0.68, 1.42) 
1.06 (0.74, 1.53) 




0.67 (0.45, 0.99)a 
0.80 (0.57, 1.13) 




1.23 (0.92, 1.67) 
1.71 (1.14, 2.58)a 










0.67 (0.42, 1.06) 
0.77 (0.55, 1.08) 




1.20 (0.77, 1.86) 
1.44 (0.95, 2.20) 




1.04 (0.67, 1.62) 
1.00 (0.67, 1.49) 




1.02 (0.71, 1.48) 
1.47 (0.94, 2.30) 
0.97 (0.61, 1.55) 
0.76 
a  Statistically Significant (p<0.05)  
1 All analyses adjusted for age and creatinine 





Chapter 4:  Discussion 
This cross-sectional analysis of thirteen phthalate metabolites revealed that 
select metabolites, specifically MCOP and MCPP, are positively associated with the 
prevalence of metabolic syndrome, with variations by gender and molecular weight, 
after adjustment for key confounders  
Of the 13 phthalate metabolites analyzed in this study, MCOP and MCPP 
consistently exhibited the strongest significant associations with MetS. MCOP has 
not previously been studied and MCPP is widely understudied in relation to 
individual MetS components. Both MCOP and MCPP are HMW metabolites and are 
widely understudied in relation to individual MetS components.  However, despite 
the limited amount of existing evidence (7,8,39,42), our study results were consistent 
with the few epidemiologic that actually examined those two metabolites. Previous 
studies by Huang(42), Tetielbaum(39) and Shiue(8) have found MCPP to be positively 
associated with increased fasting blood glucose/ insulin resistance, increased waist 
circumference and increased blood pressure respectively. Compared to MCPP, 
MCOP has not been studied in relation to individual MetS components. However, 
results from two prior studies found that individuals exposed to MCOP were at 
greater risk of experiencing oxidative stress and having inflammation markers (61).  
The prevalence of MetS was significantly higher among women in the study 
population than men. This is consistent with current national trends, which report that 
MetS rates are increasing faster among women than men (62). The strongest positive 
associations with MetS were seen in women, especially for MCOP and MCPP. 




which is consistent to results from a previous study examining phthalate exposure in 
relation to waist circumference(6). A possible explanation for this finding is that 
DEHP and DBP are anti-androgens, meaning that individuals with higher exposures 
to these compounds will have lower levels of androgens(63). Females exposed to 
androgenic compounds, such as MCPP, have higher androgen levels and are at 
greater risk of polycystic ovarian disease, higher waist circumference and metabolic 
syndrome(64). Therefore, women with higher levels of MEHP and MBP may have 
lower levels of androgens or a higher androgen/estrogen ratio, which could possibly 
explain the inverse association seen for these two metabolites and MetS.  
In addition to the observed gender differences, the odds of MetS differed by 
molecular weight group. The grouped molar sum of HMW metabolites showed a 
significantly increased odds of MetS among women whereas the grouped molar sums 
of DEHP metabolites and LMW phthalates were not associated with MetS among 
women. Prior studies have also derived indices for HMW, LMW and DEHP 
metabolites according to the individual molecular weight of each metabolites, under 
the presumptive hypothesis that molecular weight is related to potency(39). However, 
current epidemiologic evidence (39,42,46) has demonstrated mixed associations between 
HMW and LMW metabolites when examining individual MetS components. Stronger 
associations were seen for LMW metabolites (MEP, MBP) in studies examining 
obesity/waist circumference (39,49). In contrast, studies examining insulin 
resistance/diabetes in relation to phthalates found stronger odds among HMW 




been shown to have a greater affinity for metabolic disruption, oxidative stress and 
lipid accumulation in previous mechanistic studies(3).  
Previous exposure assessments on phthalates have determined that routes and 
sources of exposure are more varied among HMW metabolites in comparison to 
LMW metabolites(34). In general, exposure to phthalates occur largely through dermal 
and oral routes. However, because HMW phthalates demonstrate greater volatility 
than other phthalate metabolites, exposure may also occur via inhalation routes. 
HMW phthalates are used more widely in industrial settings then LMW metabolites, 
especially in the production of PVC and other construction materials. Because of 
these differences, it is not surprising that exposures to HMW metabolites are 
generally higher in studies using nationally representative data, MEP being the only 
exception.  
Overall, this study found that individuals exposed to specific phthalate 
metabolites had an increased odds of MetS and this association was mainly observed 
among women. While it was hypothesized that individuals with elevated levels of 
phthalate exposure would have increased odds of MetS, this did not hold true for 
some of the individual metabolites. For example, MEP had the highest urinary 
concentrations of the 13 phthalates metabolites analyzed yet this metabolite was not 
significantly associated with MetS. However, MCOP, and MCNP showed stronger 
odds of MetS, despite having lower mean concentrations than MEP. One possible 
explanation for this result is that phthalate exposure was measured at only one time 
point for this analysis, meaning that these results reflect only current exposure instead 




metabolites to be better represented in urine measurements. Typically phthalate 
metabolites have a half-life of 12-48 hours(65). However, fat deposition may lengthen 
the half-lives of metabolites due to the lipid soluble nature of phthalate 
compounds(66). Of note, this study found that the average waist circumference values 
in the sample population were much higher than the MetS cutoff value of 88cm for 
women, as defined by ATP III. This, in combination with the increase in metabolite 
half-life for individuals with greater body fat accumulation, offers perspective into 
why stronger odds of MetS were seen for women in this study.  
This present study adds to the growing body of literature showing phthalates 
to be positively associated with diseases such as diabetes and obesity, which are 
characterized by metabolic disturbances.  Evidence from animal studies suggest a 
number of potential mechanistic pathways through which phthalates may affect the 
body’s metabolism including the inactivation of hormonal receptors and the binding 
and inappropriate activation of PPARs(4). When activated by phthalates PPARs 
reduce insulin sensitivity and increase inflammatory responses resulting in greater fat 
accumulation and insulin resistance(4). Despite the growing body of supporting animal 
evidence it remains unclear whether phthalates alter these same mechanisms in 
humans. Further research is needed examining PPAR and its response to phthalates in 
humans.  
4.1 Strengths and Limitations 
This study had several limitations that should be noted. First, given the cross-
sectional study design, a temporal relationship between phthalate exposure and MetS 




excreted, the single point measurements utilized in this study may not accurately 
reflect long term phthalate exposures. Metabolites with short or long half-lives may 
be easily over or underrepresented when measuring exposure over an interval (67). 
There are a number of notable strengths to this study. This is the first study to 
examine phthalate exposures in relation to MetS.  Given the large sample size, 
differences in associations with MetS by type of phthalate and gender were examined 
which revealed significant associations by HMW metabolites among women. This 
study used clinical examination and laboratory data from NHANES in combination 
with self-reported data to assess all variables, instead of relying only on self-reported 
data, which minimizes the potential for outcome misclassification. Additional 
strengths of using NHANES data are that the sample population is well characterized 
allowing for the adjustment of several key confounders, that the study sample is 
nationally representative, rendering the findings generalizable to the U.S. population 
and that the study findings can be compared to those from prior studies of phthalate 











Phthalates are widely included in industrial, household and personal care 
products. The widespread use of contaminated products coupled with sedentary 
behaviors and genetic predispositions promote the increasing prevalence of obesity 
and cardiovascular disease in the U.S.   Establishing a relationship between phthalate 
exposure and metabolic syndrome grants insight into the risk factors of this disorder 
as well as other metabolic diseases. Because this is the first study to examine this 
relationship, study findings help identify susceptible populations and give direction to 
future analyses. Replication by longitudinal studies is needed to establish temporality 































Table A-1. Summary of previous literature 
 






























obese adults 195 
9 metabolites 
DMP, DEP, DEHP, 
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Table A-2.  Spearman correlation coefficients between phthalate metabolites 
among males in NHANES 2005-2010 
 
 mcop mcnp mecpp mnbp Mcpp mep mehhp mehp mmp minp meohp mbzp mibp 
MCOP 1 0.58 0.46 0.34 0.70 0.14 0.43 0.35 0.09 0.39 0.44 0.31 0.39 
MCNP  1 0.43 0.39 0.57 0.22 0.39 0.31 0.18 0.31 0.40 0.34 0.37 
MECPP  1 0.50 0.53 0.27 0.94 0.74 0.18 0.36 0.94 0.42 0.45 
MnBP  1 0.54 0.37 0.54 0.44 0.29 0.24 0.54 0.69 0.72 
MCPP  1 0.21 0.52 0.40 0.16 0.40 0.53 0.46 0.49 
MEP  1 0.28 0.23 0.28 0.15 0.28 0.30 0.33 
MEHHP  1 0.79 0.19 0.38 0.98 0.46 0.48 
MEHP  1 0.16 0.43 0.78 0.37 0.40 
MMP  1 0.14 0.19 0.21 0.26 
MiNP  1 0.37 0.18 0.18 
MEOHP  1 0.47 0.48 
MBzP  1 0.56 
MiBP  1 




Table A-3. Spearman correlation coefficients between phthalate metabolites 
among females in NHANES 2005-2010 
 
 mcop mcnp mecpp mnbp mcpp mep mehhp mehp mmp minp meohp mbzp mibp 
MCOP 1 0.63 0.52 0.38 0.73 0.21 0.47 0.33 0.13 0.31 0.48 0.38 0.48 
MCNP  1 0.49 0.39 0.61 0.26 0.43 0.33 0.21 0.24 0.44 0.38 0.44 
MECPP  1 0.57 0.60 0.34 0.94 0.74 0.25 0.32 0.94 0.52 0.52 
MnBP  1 0.60 0.46 0.61 0.49 0.31 0.23 0.62 0.70 0.75 
MCPP  1 0.30 0.58 0.43 0.22 0.35 0.59 0.54 0.58 
MEP  1 0.35 0.29 0.24 0.14 0.35 0.35 0.42 
MEHHP  1 0.79 0.26 0.33 0.98 0.56 0.55 
MEHP  1 0.24 0.41 0.78 0.44 0.44 
MMP  1 0.18 0.27 0.25 0.28 
MiNP  1 0.32 0.19 0.17 
MEOHP  1 0.57 0.56 
MBzP  1 0.63 
MiBP  1 
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